Chiesi Farmaceutici, an Italian pharmaceutical company, will acquire the rest of the capital of Cornerstone Therapeutics, an American company listed on the Nasdaq and focused on the marketing of specialized hospital products in the United States. Chiesi, which currently controls 58% of Cornerstone's capital, will acquire the remainder of the capital, valued at approximately $225 million, at a price of $9,5 per share in cash.
Thanks to this transaction, the Chiesi group takes an important step forward in building a wider global presence and significantly strengthens its position in the United States.
The acquisition of Cornerstone lays the foundations for new projects in the treatment of respiratory diseases and rare diseases and creates a sales channel for all the products that Chiesi intends to commercialize in the United States. The Italian company will also acquire a more prominent role in specialist medicine in the largest market in the world for this type of treatment (approximately 50% of drug projects for rare diseases originate in the United States).
